PODCAST

CME

ReachMD

science & medicine medicine

All Episodes

00:00:00

Treatment Revolution in IgA Nephropathy

CME ·

2025/09/24

Faculty: Shikha Wadhwani, MD Faculty: Dana Rizk, MD For the second episode of the KDIGO IgA Nephropathy (IgAN) podcast series, Dr. Dana Rizk and Dr. Shikha Wadhwani discuss the IgAN treatment revolution. The conversation explores how a deeper understanding of the disease's pathophysiology has led to new therapeutic options, moving beyond traditional supportive care. Key topics include: The shift in IgAN treatment since the KDIGO 2021 guidelines a The four-hit hypothesis of

00:00:00

Breaking New Ground: Acoramidis Reduces AF Events in...

CME ·

2025/08/08

Faculty: Kevin Alexander, MD This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are

00:00:00

TTR Levels and Associated Disease Risk: Insights from...

CME ·

2025/07/24

Faculty: Ahmad Masri, MD, MS Review findings from the UK Biobank presented recently at the Peripheral Nerve Society meeting, revealing that naturally low transthyretin (TTR) levels are associated with a higher prevalence of cardiovascular biomarkers, such as NT-proBNP, and comorbidities, including peripheral arterial disease, stroke, and cognitive decline. The data suggest that low TTR may serve as a marker of broader systemic illness, both in patients with TTR amyloidosis and in the

00:00:00

PH Management in Unique Patients and Conditions

CME ·

2025/07/03

Guest: Martha Kingman, DNP, FNP-C Guest: Ioana Preston, MD Guest: Jean M. Elwing, MD Pulmonary arterial hypertension (PAH) is a serious, progressive condition and successfully managing patients can present certain challenges. Treatment selection is multifactorial and often involves the consideration of myriad patient factors, including WHO Group, objective risk stratification score, cardiac functioning on imaging, and shared decision-making. And while all patients who are

00:00:00

New and Emerging PAH Therapies and Approaches: A...

CME ·

2025/07/03

Guest: Vallerie V. McLaughlin, MD Guest: Ioana Preston, MD Guest: Kelly Chin, MD, MSCA Pulmonary arterial hypertension (PAH) is a serious, progressive condition that involves making the correct diagnosis and identifying patient comorbidities as important first steps to creating a successful treatment approach. And while identifying which WHO Group a patient belongs to is key, part of the art of treating PAH is recognizing that many patients can have overlap between groups. Our

00:00:00

Impact of Finerenone on eGFR Slope by Baseline...

CME ·

2025/06/07

Guest: Finnian R. McCausland, MD These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic

00:00:00

The CONFIDENCE Trial: Data Insights

CME ·

2025/06/07

Guest: prof. Hiddo Heerspink These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of

00:00:00

Topline Results of the CONFIDENCE Trial

CME ·

2025/06/07

Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic

00:00:00

Albuminuria Change and Finerenone's Effect on CV...

CME ·

2025/06/07

00:00:00

Optimizing Barostim Outcomes: Practical Approaches to...

CME ·

2025/06/06

Host: Cynthia J. Bither, ACNP-BC, MSN Guest: Andrea Wallace, MSN, FNP-C, HF-Cert Medical devices such as Barostim – or baroreflex activation therapy (BAT) – can play an important role in improving the quality of life and providing symptom relief for patients with heart failure with reduced ejection fraction, or HFrEF. NPs and nurses are key members of the healthcare team who identify patients as potential candidates for this therapy, due in large part to their expertise in

00:00:00

Advancing Care in Non-Clear Cell RCC: Optimizing ICI...

CME ·

2025/05/09

Guest: Pedro Barata, MD, MSc, FACP Guest: Sumanta K. Pal, MD, FASCO Stay at the forefront of nccRCC care by exploring the latest advances in treatment strategies. Gain key insights into optimizing patient selection, enhancing diagnostic accuracy, and managing adverse events to improve patient outcomes. This comprehensive activity delves into emerging data, the rationale for ICI/TKI combination therapy, the latest clinical trial findings, and best practices for treatment sequencing

00:00:00

First Results From Cohort 4 of the SunRISe-1 Trial

CME ·

2025/05/01

This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along

00:00:00

Trial in Progress: Phase 3 MoonRISe-3 Study

CME ·

2025/05/01

00:00:00

Chairperson Perspective: Core Concepts for...

CME ·

2025/04/15

Host: Tycel Phillips, MD Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.

00:00:00

Mode of Death in Patients With HFmrEF/HFpEF: The...

CME ·

2025/04/01

Guest: Akshay S. Desai, MD These video briefs feature expert insights on the latest clinical data presented at ACC 2025. Leading cardiologists discuss emerging nonsteroidal mineralocorticoid receptor antagonists (MRAs), their efficacy in heart failure management, and their potential advantages over traditional steroidal MRAs. The series explores key trial findings, safety considerations, and clinical implications for optimizing patient care. Viewers will gain practical knowledge on

00:00:00

Proactive Adverse Effect Management in mCRC:...

CME ·

2025/03/31

Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

00:00:00

Case Consult: Adverse Effect Monitoring, Management,...

CME ·

2025/03/31

00:00:00

Tailoring First-Line Regimens: Patient-Centric...

CME ·

2025/03/31

Host: Harry Yoon, MD Host: Jaffer Ajani, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform

00:00:00

Strategies for Navigating First-Line Treatment...

CME ·

2025/03/31

00:00:00

Defining the Standard of Care and Optimal Sequencing...

CME ·

2025/03/31

312 results

CME

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe